 Home > Active Ingredient News > Antitumor Therapy > Phase III Clinical: Sanofi's CD38 monosaclisa significantly reduces the risk of death in patients with multiple myeloma recurrence

Phase III Clinical: Sanofi's CD38 monosaclisa significantly reduces the risk of death in patients with multiple myeloma recurrence

 Last Update: 2020-05-29
 Source: Internet
 Author: User

Tags

ritalin 10 mg

meloxicam drug test

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Sanofi's anti-CD38 monoclonal antibody, Sarclisa (isatuximab), reached the end of the trial early in a Phase III clinical trial, significantly reducing the risk of disease progression or death in patients with multiple myeloma recurrencethe randomized, multicenter, open-label Phase III clinical trial, IKEMA, was evaluated in 302 patients with multiple myeloma recurrence in 69 centers across 16 countriesall study participants received one to three previous treatments for myelomaDuring the trial, Sarclisa administered the drug in intravenously at a dose of 10 mg/kg, once a week for 4 weeks, and then for 28 days at a frequency of triweekly combinations with cafizomi and dexamethasoneSanofi said the trial reached its main endpoint in the first mid-term analysis, showing that 'in patients with multiple myeloma recurrence, Sarclisa's addition significantly longer than standard treatment with Cafezomy and dexamethasone alone.' John Reed, global head of research and development atSanofi, said: 'In this Phase III clinical trial, Sarclisa was included in the standard treatment drugs Caphyzomi and dexamethasone, and the results clearly indicate that the patient's risk of disease progression or death has been significantly reduced'
' This is Sarclisa's second Phase III positive test, further supporting the potential of our drug to improve prognosis in patients with recurrent multiple myeloma'

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Crocetin27876-94-4

CAS No.: 27876-94-4

$1-1.1/G FOB

Betulinic acid472-15-1

CAS No.: 472-15-1

$1-1.1/G FOB

1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane 53-19-0

CAS No.: 53-19-0

Pharmacy Grade

$100/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.